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post-treatment fDG pet-ct 
in head and neck carcinoma: 
comparative analysis of 4 
qualitative interpretative criteria in 
a large patient cohort
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Robin prestwich3 & Andrew Scarsbrook1,2,4
There is no consensus regarding optimal interpretative criteria (IC) for Fluorine-18 fluorodeoxyglucose 
(fDG) positron emission tomography – computed tomography (pet-ct) response assessment 
following (chemo)radiotherapy (cRt) for head and neck squamous cell carcinoma (HnScc). the aim 
was to compare accuracy of IC (NI-RADS, Porceddu, Hopkins, Deauville) for predicting loco-regional 
control and progression free survival (PFS). All patients with histologically confirmed HNSCC treated 
at a specialist cancer centre with curative-intent non-surgical treatment who underwent baseline 
and response assessment FDG PET-CT between August 2008 and May 2017 were included. Metabolic 
response was assessed using 4 different IC harmonised into 4-point scales (complete response, 
indeterminate, partial response, progressive disease). IC performance metrics (sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), accuracy) were compared. Kaplan-
Meier and Cox proportional hazards regression analyses were performed for survival analysis. 562 
patients were included (397 oropharynx, 53 hypopharynx, 48 larynx, 64 other/unknown primary). 420 
patients (75%) received CRT and 142 (25%) had radiotherapy alone. Median follow-up was 26 months 
(range 3–148). 156 patients (28%) progressed during follow-up. All IC were accurate for prediction of 
primary tumour (mean NPV 85.0% (84.6–85.3), PPV 85.0% (82.5–92.3), accuracy 84.9% (84.2–86.0)) 
and nodal outcome (mean NPV 85.6% (84.1–86.6), PPV 94.7% (93.8–95.1), accuracy 86.8% (85.6–88.0)). 
Number of indeterminate scores for NI-RADS, Porceddu, Deauville and Hopkins were 91, 25, 20, 13 
and 55, 70, 18 and 3 for primary tumour and nodes respectively. PPV was significantly reduced for 
indeterminate uptake across all IC (mean PPV primary tumour 36%, nodes 48%). Survival analyses 
showed significant differences in PFS between response categories classified by each of the four IC 
(p <0.001). All four IC have similar diagnostic performance characteristics although Porceddu and 
Deauville scores offered the best trade off of minimising indeterminate outcomes whilst maintaining a 
high npV.
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer by incidence worldwide, accounts 
for >90% of head and neck cancer, has an annual incidence of over 550,000 with around 300,000 deaths each 
year1.
The 5-year overall survival for HNSCC is 40–50% and more than two thirds of patients present with locally 
advanced disease mandating accurate staging2. Recurrence rates as high as 60% within 2 years of treatment have 
been reported with 20–30% of patients developing distant metastatic disease3. For loco-regionally advanced 
HNSCC, chemoradiotherapy (CRT) has increasingly become a standard of care.
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Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography – computed tomography (PET-CT) 
is central to characterising loco-regional and distant disease at initial staging and has an increasing role in 
post-treatment response assessment4. Randomised controlled trial data has shown that PET-CT performed 
post CRT is an accurate and cost-effective technique for assessing response and can spare 80% of patients 
from unnecessary neck dissection5. Post-treatment related changes in the neck can make assessment difficult 
in some cases, with evidence suggesting that human papilloma virus(HPV)-positive HNSCC behaves differ-
ently to HPV-negative disease, the specific test characteristics of PET-CT for assessing treatment response in 
HPV-negative HNSCC remains unclear5,6.
Semi-quantitative methods of treatment response assessment using standardised uptake value (SUV) have not 
been shown to be accurate at predicting patient outcome which has led to the development of more reproducible 
qualitative interpretative criteria (IC) to assess post-treatment response7–11. Heterogeneity in criteria used for 
assessment also limits comparison between different response assessment studies.
More recently, qualitative IC such as the Porceddu, Hopkins and Deauville scoring systems (Table 1) have 
been developed and validated in HNSCC response assessment12–14. These rely on visual inspection of the relative 
difference in tumour metabolism compared to surrounding normal tissue and/or background uptake, which in 
the case of Hopkins is the internal jugular vein and in Deauville, is the mediastinal blood pool. Both Hopkins and 
Deauville criteria use 5-point scales, however scores 1 and 2 in both categories effectively represent a complete 
metabolic response. Porceddu criteria employ a 3-point scale which classifies scans as positive, negative or equiv-
ocal based on whether there is FDG activity greater than adjacent normal tissues and/or liver12.
Several studies have reported that qualitative assessment methods are useful for predicting regional control 
and can help minimise the number of equivocal scan results13,15,16. In 2016, the American College of Radiology 
convened a Neck Imaging Reporting and Data Systems (NI-RADS) Committee who have developed a template 
to help distinguish benign post-treatment changes and residual or recurrent tumour17.
Score FDG Uptake Category
Porceddu
1
No residual FDG activity above 
background or diffuse uptake in the 
absence of a corresponding suspicious 
structural abnormality
Negative
2
FDG activity greater than adjacent 
normal tissues but below background 
liver activity
Equivocal
3
Focal uptake corresponding to a 
structural abnormality of greater 
intensity than background liver
Positive
Hopkins
1 Minimal uptake (<internal jugular vein (IJV))
Complete metabolic response 
(CMR)
2 Minimal uptake (>IJV but <liver) Probably CMR
3 Diffuse uptake (>IJV and liver) Probably post radiation inflammation
4 Moderate focal uptake (>liver) Probably persistent tumour
5 Intense focal uptake (>liver) Persistent tumour
Deauville
1 No uptake CMR
2 Minimal uptake (<mediastinal blood pool (MBP)) Probably CMR
3 Low-grade uptake (>MBP but <liver) Probably post radiation inflammation
4 Moderate focal uptake (>liver) Probably persistent tumour
5 Intense focal uptake (>2 × liver) or new lesions Persistent tumour
NI-RADS
0 Incomplete imaging Incomplete
1
No abnormal FDG uptake/Diffuse 
linear mucosal enhancement after 
radiation
No recurrence
2
Focal mucosal enhancement, but non 
mass-like or focal mild to moderate 
mucosal FDG uptake
Low suspicion
3 New or enlarging primary mass or lymph node or Intense focal uptake High suspicion
4 Pathologically proven or definite radiological and clinic progression Definite recurrence
Table 1. Response interpretation criteria and explanation of each category.
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Currently there is no clear consensus regarding the optimal IC to use in this clinical scenario. Classifying 
‘equivocal’ cases varies depending on which IC is used and differences remain in how these patients are sub-
sequently managed, for example, undergoing invasive neck dissection or further follow-up imaging and clin-
ical examination given the difficulty in differentiating a benign post-treatment response or residual/recurrent 
tumour18.
The primary objective of this study was to assess comparative accuracy and prognostic ability of the 4 dif-
ferent IC (NI-RADS, Porceddu, Hopkins and Deauville) in a large cohort of HNSCC patients treated with 
curative-intent (chemo)radiotherapy for predicting local and regional disease control and progression free sur-
vival (PFS).
Methods
patient cohort. The study involved retrospective analysis of a prospective database performed under 
a waiver of informed consent and ethics approval by the Institutional Review Board. Prospective consent was 
obtained from all patients for use of their PET-CT imaging data in research and service development projects. 
Consecutive patients with histologically confirmed HNSCC treated at a tertiary referral centre between August 
2008 and May 2017 with curative-intent non-surgical treatment (radiotherapy alone or chemoradiotherapy) who 
had undergone baseline and response assessment FDG PET-CT. Our institutional protocol is for response assess-
ment PET-CT to be performed approximately 4 months after treatment. Demographics, baseline characteristics, 
staging, treatment and outcome details were retrieved from the institutional electronic patient record (PPM+, 
Leeds, United Kingdom). Exclusion criteria included: patients with nasopharyngeal carcinoma; previous resec-
tion of primary or nodal disease; prior radiotherapy; FDG PET-CT only performed at baseline or for response 
assessment
treatment. Patients were treated with either three-dimensional (3D)-conformal radiotherapy or 
intensity-modulated radiotherapy (IMRT), which was gradually introduced into routine clinical practice from 
2010. The 3D-conformal radiotherapy technique19 and IMRT20 have been previously described. Institutional pro-
tocols were followed with a radical treatment dose of 70 Gy in 35 fractions over 7 weeks or 65 Gy in 30 fractions 
over 6 weeks, with lower doses to prophylactic dose regions (54–63 Gy in 35 fractions over 7 weeks).
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) or cisplatin and 5-fluorouracil 
(PF) were delivered to a proportion of patients as previously described21. Concurrent chemotherapy routinely 
consisted of cisplatin 100 mg m−2 at days 1 and 29.
Response assessment and follow-up. Tumour response was routinely assessed by clinical examina-
tion, naso-endoscopy where appropriate and FDG PET-CT approximately 4 months after completing treatment. 
Examination under anaesthetic and biopsies were performed at clinical discretion following response assessment. 
In general, patients who achieved a complete metabolic response did not undergo biopsy. Patients with less than 
a complete response were managed on an individual basis based upon discussion at a multidisciplinary team 
meeting. Subsequently, patients were followed up with physical examination and flexible endoscopy every 6–8 
weeks in the first year after treatment, every 3 months for an additional 2 years and every 6 months until discharge 
at 5 years22.
pet-ct technique. FDG PET-CT examinations prior to June 2010 were performed on a 16-slice Discovery 
STE PET-CT scanner (GE Healthcare, Chicago, Illinois, USA) and from June 2010 to October 2015 on a 64-slice 
Gemini TF64 scanner (Philips Healthcare, Best, Netherlands), After October 2015 all scans were performed 
on a 64-slice Discovery 710 scanner (GE Healthcare, Chicago, Illinois, USA). Serum blood glucose was rou-
tinely checked and if >10 mmol/L scanning was not performed. Patients fasted for 6 hours prior to intravenous 
Fluorine-18 FDG injection (dose varied according to patient body weight). PET acquisition from skull vertex 
to upper thighs was performed 60 minutes after tracer injection. A silence protocol was employed in the uptake 
period following tracer injection to minimize physiological tracer activity within the head and neck region. 
The CT component was performed according to a standardized protocol (without the use of iodinated contrast 
medium) with the following settings: 120 kV; auto-modulated mAs; tube rotation time, 0.5 seconds per rotation; 
pitch, 6; section thickness, 2.5 mm (to match the PET section thickness).
Patients maintained normal shallow respiration during the CT acquisition. Images were reconstructed using a 
standard ordered subset expectation maximization (OSEM) algorithm with CT for attenuation correction. Both 
non-attenuation-corrected and attenuation corrected datasets were reconstructed.
image analysis. All response assessment PET-CT studies were evaluated by a trainee radiologist under 
supervision of a dual-accredited Radiologist & Nuclear Medicine Physician with 15 years’ experience of report-
ing oncological PET-CT using specialised software (Advantage Windows Version 4.5, GE Healthcare, Chicago, 
Illinois, USA) and each of the four IC were applied. To accurately compare all four response assessment scales, 
each scale was re-classified into a 4-point scale as shown in Table 2 with complete response, partial response, 
indeterminate and progressive disease categories. Representative examples of these 4 categories are shown in 
Fig. 1.
clinical follow-up. Follow-up was defined from final fraction of radiotherapy treatment. Disease status 
post-treatment was determined from pathology and/or radiology correlation with review of electronic patient 
records for clinical outcome. In patients who did not receive a biopsy/surgical intervention, serial negative phys-
ical examinations over the follow-up period and any relevant imaging investigations were used as confirmation 
of disease-free status.
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Statistical analysis. Survival and recurrence time was defined from final fraction of radiotherapy treat-
ment. Diagnostic performance metrics for each IC: sensitivity, specificity, positive predictive value (PPV), neg-
ative predictive value (NPV) and overall accuracy applied to both primary tumour and nodes were calculated. 
Performance in sub-groups including HPV-positive oropharyngeal cancers (OPC), HPV-negative OPC and 
hypopharynx/larynx cancers were analysed.
Univariate association between recurrence (local and/or regional and/or distant) and each adjusted response 
assessment score (1–4) was estimated by the Chi-squared test. Kaplan-Meier analysis and Cox proportional haz-
ards regression analyses were performed for each IC to assess cumulative progression free survival (PFS) and 
time to death (overall survival, OS) or progression. Log-rank testing was used to compare survival between the 
response categories within each IC. Receiver-operating characteristic (ROC) curve analysis was performed for 
Response category NI-RADS Porceddu Hopkins Deauville
1. Complete 
response 1 0 1 + 2 1 + 2
2. Indeterminate 2 1 3 3
3. Partial response 3 2 4 4
4. Progressive 
disease 4 3 5 5
Table 2. Harmonisation process of each interpretative criteria into standardized 4-point scales.
Figure 1. Representative cases illustrating post-harmonisation interpretative categories (1 to 4) pre and post-
treatment. Row 1 – Complete response, Row 2 – Indeterminate, Row 3 – Partial response, Row 4 – Progressive 
disease.
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each IC. The statistical significance level was set at P < 0.05. All statistical tests were performed using SPSS for 
Windows software (Version 21.0; IBM Corp., Armonk, New York, USA).
Results
patient characteristics. A total of 562 patients were included in analysis. Detailed patient characteristics 
are provided in Table 3. Median age was 58 years (range 24–84). The median (range) of baseline tumour SUVmax 
and nodal SUVmax were 11.0 (0–53) and 8.1 (0–34) respectively. Median response tumour SUVmax was 1.7 (0–14.3) 
and nodal SUVmax was 1.0 (0–12.5).
outcomes. Median follow-up period was 26 months (range 3–148 months). Median time from end of treat-
ment to response assessment PET-CT was 17 weeks (range 6–31 weeks). 2-year survival outcomes were as follows: 
PFS 73%; OS 79%; local PFS 89%; regional PFS 85%; distant PFS 88%.
130 patients (23%) died in the study period with 432 patients (77%) alive at the time of analysis. 13 patients 
(2%) died within 6 months of treatment; one from a sudden cardiac event, two from tumor haemorrhage and 
10 from disease progression. During follow-up, 156 patients (28%) developed progressive disease, 31 (20%) at 
the primary tumour site only (local failure), 42 (27%) at a regional nodal site only (regional failure), 16 (10%) 
at both the primary tumour and nodal site (loco-regional failure) without distant metastases and 35 (22%) had 
distant metastases only. 32 patients (21%) had local and/or regional failure with distant metastases. 11 cases (7%) 
of progressive disease were biopsy proven, 144 (92%) were based on radiology and 1 was a clinical diagnosis. 22 
Characteristics Number %
Gender
Male 423 75
Female 139 25
Smoking
Smoker 205 36.5
Ex-smoker 176 31
Never smoked 149 26.5
Not recorded 32 6
Tumour site
Paranasal sinus 9 2
Oral cavity 7 1
Oropharynx 397 71
Hypopharynx 53 9
Larynx 48 8.5
Unknown 48 8.5
Grade
Well differentiated 7 1
Moderately differentiated 118 21
Poorly differentiated/ 
basaloid 364 65
Undifferentiated 6 1
Not recorded 67 12
HPV status
Positive 228 40
Negative 55 10
Not recorded 279 50
T stage
TX 47 8
T1 101 18
T2 188 34
T3 120 21
T4 106 19
N stage
N0 81 14
N1 61 11
N2a 42 8
N2b 274 49
N2c 99 18
N3 5 1
Stage group 
(AJCC)
I 4 1
II 24 4
III 80 14
IV 454 81
Treatment
CRT 420 75
RT only 142 25
Table 3. Patient characteristics.
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of 35 patients who developed distant metastases had these detected on response assessment PET-CT, 13 patients 
developed metastatic disease subsequently. Median time to loco-regional recurrence was 4 months (range 2–53).
Kaplan-Meier, the log-rank test and Cox proportional hazards regression analyses showed significant differ-
ences in PFS and OS between response categories classified by each of the four IC (p < 0.0001). Pairwise log-rank 
results provided in supplementary information. The survival curves pre and post harmonisation are shown in 
Figs. 2 and 3.
indeterminate cases. The number of indeterminate scores varied for each IC as shown in Table 4. With 
regards to primary tumour, NI-RADS classified 91 patients as indeterminate compared to 25 for Porceddu, 20 
for Deauville and 13 for Hopkins. Overall, the NI-RADS IC scored more cases than the other 3 IC combined as 
indeterminate i.e. equivocal. Hopkins scored the fewest number of indeterminate cases.
Diagnostic performance of interpretation criteria. The diagnostic performance of each IC in predict-
ing disease control with regard to primary tumour, nodal disease, HPV-positive OPC, HPV-negative OPC and 
hypopharynx/larynx sub-groups are displayed in Table 5. The performance of each IC in predicting complete 
response and progressive disease in the indeterminate groups is shown in Table 6.
The ROC analysis (Fig. 4) established that each of the IC were similar in their ability to predict disease out-
come with areas under the curve (AUC) of 0.76 (NI-RADS), 0.76 (Porceddu), 0.75 (Hopkins) and 0.76 (Deauville) 
respectively.
Discussion
The use of qualitative assessment of FDG PET-CT post treatment in HNSCC was highly predictive of PFS and OS 
using four previously validated criteria - NI-RADS, Porceddu, Hopkins and Deauville in our large patient cohort. 
All 4 adjusted IC demonstrated good discriminatory ability in predicting disease outcome with high specificity, 
PPV and NPV which could help clinical decision making, stratifying patients into different management streams 
including continued observation, biopsy or salvage surgery.
Figure 2. Kaplan-Meier plots of progression free survival based on each primary interpretative criteria before 
harmonisation. NI-RADS criteria (Categories 1–4), Porceddu criteria (Categories 1–3), Hopkins criteria 
(Categories 1–5) and Deauville criteria (Categories 1–5).
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Compared to the existing literature, the PPV values of our study (83–95%) are slightly higher than other 
reported rates of 51–78%14,15,23. Diagnostic accuracy of response assessment PET-CT is affected by the time inter-
val between treatment and follow-up imaging, the later median time-point of imaging post radiotherapy (17 
weeks) compared to other studies may account for the slightly higher PPV values in this study. Conversely the 
NPV is lower (84–86%) compared to multiple other studies (86–97%) with smaller cohort sizes (largest 214 
patients)12,13,23–25. PET-CT was categorised as false-negative if recurrent cancer was diagnosed at any stage dur-
ing follow-up, the longest time to progression recorded was over 50 months from the end of treatment, whereas 
other studies limited this period to 6 months after the response assessment PET (1423, and had a higher NPV. A 
comparable study assessing Deauville criteria for nodal response assessment post CRT in 105 HNSCC patients 
using the same methodology for false-negatives (any time during follow-up) had a similar NPV (86.4%) (13). 
By restricting false negatives to those with recurrence developing within 6 months, the NPV of NI-RADS as an 
example, increases from 85% to 94% in our cohort.
Figure 3. Kaplan-Meier plots of progression free survival based on each interpretative criteria post-
harmonisation into 4-point scales.
Group
NI-RADS Porceddu Hopkins Deauville
N R (%) N R (%) N R (%) N R (%)
All Tumour 91 38 (42%) 25 7 (28%) 13 6 (46%) 20 6 (30%)
All Node 55 32 (58%) 70 21 (30%) 3 3 (100%) 18 10 (56%)
HPV + ve OPC 32 11 (34%) 9 2 (22%) 4 2 (50%) 8 2 (25%)
HPV − ve OPC 9 5 (56%) 2 2 (100%) 1 1 (100%) 1 1 (100%)
Hypopharynx/Larynx 23 10 (43%) 2 1 (50%) 3 0 (0%) 2 1 (50%)
Table 4. Indeterminate scores as categorised according to different interpretative criteria for each analysis 
group (All primary tumour, all node, HPV-positive OPC, HPV-negative OPC and hypopharynx/larynx sub-
groups). Key: N = total number of cases. R = number of cases with disease recurrence (percentage calculation 
of number of cases recurred as a proportion of total number of indeterminate cases for the group) OPC = 
oropharyngeal cancer.
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There was greater variation in the number of cases classified as indeterminate between different IC, with far more 
scores in this category when applying the NI-RADS IC. This likely reflects the subjective nature of the NI-RADS inde-
terminate group which includes all cases which have focal mild to moderate mucosal FDG uptake without giving a 
reference area of uptake such as the IJV (Hopkins) or mediastinum (Deauville) thereby making it more difficult to split 
these cases up compared to the other IC17,26. The overall mean recurrence rate of 53% (range 42–69%) in NI-RADS 
category 2 (low suspicion for recurrence) patients in this study is also much higher than previously reported research 
study figures of 17.2%, highlighting that more work in large cohort studies is required to validate this26. One advantage 
identified for the Hopkins IC is the low number of indeterminate cases however the NPV was lower, particularly for 
HPV-positive (87.6%) and HPV-negative (77.4%) groups. Porceddu and Deauville provided the best trade off mini-
mising indeterminate scores whilst maintaining a high NPV. Individual centres should apply one IC consistently across 
all patients to facilitate more standardised reporting and allow for future comparisons between institutions.
Interestingly, the NPV for HPV-positive OPC patients was higher than for the HPV-negative sub-group. 
Fakhry et al. previously reported that HPV-positive status was a good prognostic indicator with better CRT sen-
sitivity and patient outcome27. This is relevant in indeterminate cases, where use of these IC may provide more 
information on guiding optimal management between neck dissection or surveillance. Previous research has 
demonstrated no association between HPV status and other semi-quantitative imaging markers in relation to 
predicting recurrence28. The higher NPV in HPV-positive patients may be potentially useful for clinicians when 
considering additional treatments such as neck dissection.
The prognostic value of PET is more uncertain when FDG uptake is equivocal/indeterminate across all four 
IC, with a low PPV, although this observation is limited by a relatively low number of cases fitting this sub-group 
with a median number of 22 for all tumour and node cases although this group was as low as one in the HPV 
status and hypopharynx/larynx subgroup analysis. The ability to more accurately distinguish between benign 
post-treatment inflammation or residual disease remains of paramount clinical importance as each scenario 
would require significantly different patient management. In longitudinal PET studies assessing lymphoma, 
equivocal scans have proved to represent a good rather than bad prognosis29. In the meantime, as advocated by 
the IC such as NI-RADS, indeterminate cases may be best followed up non-invasively with imaging in the form 
NI-RADS Porceddu Hopkins Deauville Mean
All Primary Tumour
Sensitivity 47.06 55.46 52.8 52.99 52.1
Specificity 98.72 95.64 95.86 96 96.6
PPV 92.31 82.5 82.5 82.67 85.0
NPV 85.08 85.28 84.6 85.01 85.0
Accuracy 85.99 84.77 84.23 84.62 84.9
All Node
Sensitivity 47.37 57.43 48.33 50.91 51.0
Specificity 99.04 98.93 99.09 99.07 99.0
PPV 93.75 95.08 95.08 94.92 94.7
NPV 86.15 86.6 84.06 85.52 85.6
Accuracy 87.04 87.96 85.56 86.81 86.8
All HPV-positive OPC
Sensitivity 44.44 61.54 42.11 45.45 48.4
Specificity 99.35 99.28 99.36 99.36 99.3
PPV 92.31 94.12 94.12 93.75 93.6
NPV 91.12 93.24 87.64 89.6 90.4
Accuracy 91.21 93.33 88.21 89.95 90.7
All HPV-negative OPC
Sensitivity 61.54 64.29 56.25 60 60.5
Specificity 96 96 96 96 96.0
PPV 88.89 90 90 90 89.7
NPV 82.76 82.76 77.42 80 80.7
Accuracy 84.21 84.62 80.49 82.5 83.0
All Hypopharynx/Larynx
Sensitivity 32.14 44.12 42.86 44.12 40.8
Specificity 100 (9) 93.75 93.88 93.75 93.8
PPV 100 (9) 83.33 83.33 83.33 57.9
NPV 70.31 70.31 69.7 70.31 70.2
Accuracy 73.97 73.17 72.62 73.17 73.2
Table 5. Diagnostic performance of interpretative criteria for prediction of complete response and progressive 
disease applied to all primary tumours, all nodal disease, HPV-positive OPC, HPV-negative OPC and 
Hypopharynx/Larynx sub-groups. Mean values for each diagnostic performance metric across all 4 IC are also 
provided. () = number of cases provided. Key: OPC = oropharyngeal cancer.
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of a contrast-enhanced CT or PET17. One option is to perform a second interval PET-CT response assessment. 
Porceddu et al. recommend a further repeat PET-CT 4–6 weeks later (16 weeks post treatment) if the first one 
shows indeterminate response, with no subsequent cases of nodal failure12. Similarly a recent publication from 
our group highlighted that a second-look PET-CT 13 weeks median duration from the first response assessment 
PET-CT (median 30 weeks post treatment) found the majority of incomplete response cases convert to a com-
plete metabolic response30. Follow-up imaging at an earlier time point results in a higher number of false positive 
results31. This warrants future evaluation in a larger prospective cohort.
Inter-observer agreement of IC was not assessed in this study mainly because previous work has shown these 
IC to be highly reproducible14,16. Limitations include the retrospective study design, heterogenous patient cohort 
with different sites of HNSCC and the slight difference in treatment with the majority having CRT but a small 
group having radiotherapy only.
Emerging studies exploring the utility of radiomic features extracted from head and neck cancers highlight 
the potential for more accurate prediction of disease progression using novel imaging signatures which could be 
augmented by artificial intelligence techniques32–34. Although there is no current clinical implementation of a 
radiomic-based decision-support system in this clinical scenario, in the future this may emerge and could result 
in better patient stratification and personalization of treatment34. Some challenges remain ahead of this including 
a need for greater data transparency, multi-centre collaborations for cross-validation and to confirm reproduci-
bility of radiomic analysis methods34.
NI-RADS (n = 91)
Porceddu 
(n = 25)
Hopkins 
(n = 13)
Deauville 
(n = 20) Mean
All Primary Tumour
Sensitivity 41 11.67 9.23 9.84 17.9
Specificity 85 94.46 97.89 95.71 93.3
PPV 41.76 28 46.15 30 36.5
NPV 85.08 85.28 84.6 85.01 85.0
Accuracy 76.38 81.56 83.3 82.17 80.9
All Node
NI-RADS (n = 55) Porceddu (n = 70)
Hopkins 
(n = 3)
Deauville 
(n = 18) Mean
Sensitivity 39.02 32.81 4.62 15.62 23.0
Specificity 93.11 85.02 100 97.55 91.9
PPV 58.18 30 100 55.56 47.9
NPV 86.15 86.6 84.06 85.52 85.6
Accuracy 82.45 76.47 84.18 84.14 81.8
All HPV-positive OPC
NI-RADS (n = 32) Porceddu (n = 9)
Hopkins 
(n = 4)
Deauville 
(n = 8) Mean
Sensitivity 42.31 56.52 4.35 21.74 31.2
Specificity 96.86 88.46 100 99.36 94.9
PPV 68.75 41.94 100 83.33 64.7
NPV 91.12 93.24 87.64 89.6 90.4
Accuracy 89.19 84.36 87.71 89.39 87.7
All HPV-negative OPC
NI-RADS (n = 9) Porceddu (n = 2)
Hopkins 
(n = 1)
Deauville 
(n = 1) Mean
Sensitivity 50 28.57 12.5 14.29 26.3
Specificity 85.71 100 100 100 85.7
PPV 55.56 100 100 100 55.6
NPV 82.76 82.76 77.42 80 80.7
Accuracy 76.32 83.87 78.12 80.65 79.7
All Hypopharynx/Larynx
NI-RADS (n = 23) Porceddu (n = 2)
Hopkins 
(n = 3)
Deauville 
(n = 2) Mean
Sensitivity 34.48 5 0 5 14.8
Specificity 77.59 97.83 93.88 97.83 91.8
PPV 43.48 50 0 50 47.8
NPV 70.31 70.31 69.7 70.31 70.2
Accuracy 63.22 69.7 66.67 69.7 67.3
Table 6. Diagnostic performance of interpretative criteria for prediction of complete response and progressive 
disease for indeterminate scores applied to all primary tumours, all nodal disease, HPV-positive OPC, 
HPV-negative OPC and hypopharynx/larynx sub-groups. () = number of indeterminate cases. Key: OPC = 
oropharyngeal cancer.
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conclusion
Assessment with FDG PET-CT post-treatment in HNSCC is accurate for prediction of complete response or 
disease progression. All four analysed IC have similar diagnostic performance characteristics however Porceddu 
and Deauville provide the best trade off minimising indeterminate scores whilst maintaining a high NPV.
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